Arcus Biosciences Stock Forecast

Stock Price Forecast

According to 13 analysts polled by S&P Global, Arcus Biosciences stock has a consensus rating of "Strong Buy" and an average price target of $35.75. The average 1-year stock price forecast is 50.21% higher than the current stock price, while the lowest is $22 (-7.56%) and the highest is $47 (+97.48%).

Price Target: $35.75 (+50.21%)

Analyst Consensus: Strong Buy

Target	Low	Average	Median	High
Price	$22	$35.75	$34.5	$47
Change	-7.56%	+50.21%	+44.96%	+97.48%

Analyst Ratings

The average analyst rating for Arcus Biosciences stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.

Recommendation Trends

Rating	Jan '26	Feb '26	Mar '26	Apr '26	May '26	Jun '26
Strong Buy	10	9	9	9	9	10
Buy	0	0	0	0	0	0
Hold	2	3	3	3	3	3
Sell	0	0	0	0	0	0
Strong Sell	0	0	0	0	0	0
Total	12	12	12	12	12	13

Latest Forecasts

Analyst	Firm	Rating	Rating	Action	Price Target	Upside	Date
Supawat Thongthip Truist Financial	Truist Financial	Buy Maintains n/a	Buy	Maintains	n/a	n/a	Jun 4, 2026
Charles Zhu LifeSci Capital	LifeSci Capital	Buy Initiates $46	Buy	Initiates	$46	+93.28%	Jun 4, 2026
Emily Bodnar H.C. Wainwright	H.C. Wainwright	Buy Maintains $32	Buy	Maintains	$32	+34.45%	Jun 3, 2026
Terence Flynn Morgan Stanley	Morgan Stanley	Hold Maintains $20 → $22	Hold	Maintains	$20 → $22	-7.56%	May 11, 2026
Richard Law CFA Goldman Sachs	Goldman Sachs	Buy Maintains $30 → $34	Buy	Maintains	$30 → $34	+42.86%	May 7, 2026

More Analyst Ratings

Financial Forecast

Revenue This Year

85.06M

from 247.00M

-65.56%

from 247.00M

Revenue Next Year

93.06M

from 85.06M

9.40%

from 85.06M

EPS This Year

-3.48

from -3.29

EPS Next Year

-3.10

from -3.48

Fiscal Year	FY 2021	FY 2022	FY 2023	FY 2024	FY 2025	FY 2026
Period Ending	Dec 31, 2021	Dec 31, 2022	Dec 31, 2023	Dec 31, 2024	Dec 31, 2025	Dec 31, 2026
Revenue	383.00M	112.00M	117.00M	258.00M	247.00M	85.06M
Revenue Growth	391.03%	-70.76%	4.46%	120.51%	-4.26%	-65.56%
Gross Profit	126.00M	-176.00M	-223.00M	-190.00M	-276.00M	85.06M
Gross Margin	32.90%	-157.14%	-190.60%	-73.64%	-111.74%	100.00%
Operating Income	54.00M	-280.00M	-340.00M	-310.00M	-386.00M	-492.61M
Net Income	53.00M	-267.00M	-307.00M	-283.00M	-353.00M	-456.38M
EPS	-	-	-	-	-3.29	-3.48
Free Cash Flow	-644.75M	617.75M	-187.75M	-41.25M	-162.25M	-258.50M
No. Analysts	-	-	-	-	-	12

EPS and Forward PE are based on non-GAAP adjusted numbers.

Revenue Forecast

Revenue	2026	2027	2028
High	152.0M
Avg	85.1M
Low	53.4M

Revenue Growth

Revenue Growth	2026	2027	2028
High	-38.5%
Avg	-65.6%
Low	-78.4%

EPS Forecast

EPS	2026	2027	2028
High	-2.63
Avg	-3.48
Low	-4.88

EPS Growth

EPS Growth	2026	2027	2028
High	-
Avg	-
Low	-